When the Malaysia Agreement 1963 was signed, Sarawak’s healthcare landscape reflected its status as a newly federated state with vast geographical challenges and limited infrastructure.
The public health burdens of the time were formidable, particularly from waterborne diseases that thrived in the absence of clean water infrastructure.
A longitudinal study published in the Transactions of The Royal Society of Tropical Medicine and Hygiene examining health data from 1963 to 2002 found that water supply interventions contributed to a more than 200-fold decrease in dysentery and a 60-fold decrease in enteric fever over that period, demonstrating the profound impact of basic public health measures in the decades immediately following federation.
Sixty years later, this Bornean state stands on the cusp of full health autonomy, having transformed itself from a medically underserved territory into an unexpected powerhouse of clinical research and digital health innovation.
The journey from wooden rural clinics to conducting global first-in-human cancer drug trials represents one of Southeast Asia’s most compelling healthcare transformation stories.
At the formation of Malaysia in 1963, Sarawak’s healthcare system reflected the legacy of Brooke rule and brief British colonial administration.
The state’s dispersed population of approximately 800,000 people spread across 124,450 square kilometres presented formidable challenges for healthcare delivery.
Medical services concentrated in coastal towns, leaving interior communities dependent on river transport and longhouse-based traditional medicine.
The first two decades after MA63 saw gradual expansion of rural health infrastructure, and by 1970 Sarawak had established 42 static dispensaries and 22 travelling dispensary routes serving interior communities.
These facilities, typically staffed by hospital assistants and rural nurses rather than qualified doctors, represented the extent of mainstream medical services for most indigenous communities.
Sarawak General Hospital in Kuching functioned as the state’s sole referral centre throughout this period, having originally been established in 1923 and undergoing significant expansion in the 1970s and 1980s, gradually developing specialist departments.
However, consultant coverage remained thin, and as late as 1990 Sarawak had fewer than 50 specialist doctors serving a population approaching 1.5 million.
The geographical reality meant that patients requiring specialist intervention faced extraordinary journeys, with a seriously ill patient from Belaga or Bario requiring days of travel by logging road, river, and air to reach Kuching.
This spatial inequity would become a central concern in Sarawak’s healthcare advocacy for decades to come.
Even as infrastructure developed, infectious disease surveillance remained critical, with research from the Faculty of Medicine and Health Sciences at Universiti Malaysia Sarawak documenting the seroepidemiology of leptospirosis among communities living in periurban areas, contributing to the understanding of emerging zoonotic diseases in the state’s rapidly changing environment.
A pivotal moment in Sarawak’s medical development came in 1998 with the establishment of the state’s neurosurgery department, which represented more than clinical expansion as it signalled Sarawak’s ambition to develop tertiary services that reduced dependence on Peninsular Malaysia.
The department’s growth trajectory illustrates Sarawak’s broader specialist development, from a single neurosurgeon in 1998 to 19 specialists today, with 15 remaining in public service, a retention rate that challenges the narrative that East Malaysian states cannot maintain specialist workforce.
Neurosurgery’s development enabled Sarawak to manage complex cases previously requiring referral to Kuala Lumpur or Singapore, and trauma patients with head injuries, disproportionately common in a state with extensive logging and mining operations, could now receive life-saving intervention within the golden hour when transferred to Kuching, though geographical barriers persisted for those injured in the state’s interior.
The 1990s and 2000s saw progressive strengthening of hospitals in Sibu, Miri, and Bintulu, with these facilities developing core specialist services and creating a three-region referral network that reduced pressure on Sarawak General Hospital.
By 2010, Sibu Hospital had established itself as the primary referral centre for the Central Region, serving the Rejang basin population from its 550-bed facility.
Yet infrastructure development struggled to keep pace with population growth and disease transition, as Sarawak’s population reached 2.4 million by 2010 with rising rates of non-communicable diseases including cardiovascular conditions and cancer.
The state’s cancer services remained concentrated in Kuching, with patients from the north travelling up to 800 kilometres for radiotherapy.
The changing disease profile demanded new research approaches, and by 2025, investigators were publishing population-based analyses documenting incidence trends of prostate cancer in Sarawak over a 20-year period, as well as twenty-year reviews of uterine cancer epidemiology, establishing the evidence base for oncology service planning in the state’s diverse populations.
Global Pharmaceutical Research
The most remarkable chapter in Sarawak’s medical story unfolded in the 2020s, as Sarawak General Hospital emerged as an unexpected destination for global pharmaceutical research.
Before 2023, Malaysia had never conducted a first-in-human clinical trial, the crucial research step where new drugs are tested on people for the first time.
This changed dramatically when Sarawak General Hospital became the first Malaysian site to conduct such trials, and by late 2025 Sarawak had conducted eight first-in-human cancer drug trials, representing a third of all such trials globally for new oncology drugs.
Of the 25 new cancer drugs developed and marketed worldwide, eight have a footprint in Sarawak, an extraordinary concentration for a single hospital in a state of fewer than three million people.
The significance extends beyond prestige, as these trials generate research income exceeding RM50 million annually, funding 40 research assistants in the oncology department alone without government allocation.
This revenue stream, derived from international pharmaceutical companies, represents a new model of healthcare financing that Sarawak is uniquely positioned to leverage. In 2024, Sarawak General Hospital received the national Best Medical Research Hospital Award for the first time a Bornean institution claimed this honour.
More significantly, Swiss pharmaceutical giant Roche selected Sarawak General Hospital as the sole Asia-Pacific hospital invited to test its new solid tumour drug, a decision that bypassed Singapore General Hospital and other regional centres with longer research pedigrees.
Deputy Premier Dr Sim Kui Hian, himself a consultant cardiologist, frames these achievements as evidence of Sarawak’s capacity for health autonomy, explaining that worldwide there are only about 30 sites that meet these standards and that you cannot just say you want to be a first-in-human site because these sites are monitored very strictly, not just by Malaysians but by the companies themselves.
Beyond first-in-human trials, Sarawak has conducted over 255 clinical trials across all phases, with the oncology department alone completing 72 studies, placing Sarawak among Malaysia’s top contributors with 155 trials conducted across 267 national sites.
The research infrastructure supporting these trials demonstrates sophisticated capability, as international pharmaceutical companies do not entrust drug development to sites lacking rigorous data management, ethical oversight, and clinical governance. Sarawak’s emergence as a trial hub signals that its institutions meet global standards, a powerful argument for expanded autonomy.
Parallel research capacity has developed in infectious diseases, with investigators contributing to One Health research collaborations addressing emerging and re-emerging infectious diseases through international partnerships, including studies on the effectiveness of vero cell inactivated vaccine against severe acute respiratory infections in Sibu using retrospective test-negative designs.
These complementary research streams in oncology, vaccinology, and zoonotic diseases position Sarawak as a multifaceted research environment capable of addressing diverse health challenges.
While clinical research garners international attention, Sarawak is simultaneously pursuing a domestic transformation with profound implications for rural healthcare access, aiming to become Malaysia’s first fully digitalised health system by 2026.
As of November 2025, 175 of Sarawak’s 270 public health clinics, representing 73 per cent, have implemented the Clinic Care Management System, eliminating paper case notes for nearly three-quarters of clinic patients.
Authorised providers can now access medical histories, test results, and medication records online across digitalised facilities, a critical capability in a state where patients often present to different clinics as they move between urban and rural areas.
Digitalisation Initiative
The digitalisation initiative received RM10 million in Phase 1 funding covering 150 clinics, with the Sarawak government providing this allocation rather than federal funds, illustrating the state’s willingness to invest its own resources in health infrastructure.
Deputy Premier Dr Sim emphasises digitalisation’s equity implications, noting that most importantly, patients from these 175 clinics in Sarawak no longer need to carry their paper case notes.
For elderly patients and those with limited literacy, paperless systems reduce the risk of lost documentation and interrupted care.
The remaining 94 clinics require internet infrastructure development, with state agencies working to ensure connectivity reaches remote locations by 2026.
Upon completion, Sarawak will achieve what no other Malaysian state has attempted: universal digital health records across all government clinics.
Digitalisation represents Phase 1 of a broader strategy, as Sarawak plans to explore healthcare artificial intelligence applications including medical diagnostics, predictive analytics, telemedicine for virtual consultations, and hospital efficiency systems.
These technologies hold particular promise for rural Sarawak, where specialist shortages persist despite overall workforce growth.
The convergence of digital infrastructure with Sarawak’s research capabilities creates unique opportunities, as real-world data from digitalised clinics could support research applications, potentially attract further pharmaceutical investment and enable Sarawak to participate in precision medicine initiatives.
The research ecosystem also supports behavioural interventions, with study protocols developed for randomised controlled trials examining structured group-based educational programs to improve medication adherence among patients with type 2 diabetes mellitus in Sarawak, demonstrating the breadth of health services research underway alongside clinical and laboratory investigations.
Sarawak’s Healthcare Challenges
Despite impressive achievements in Kuching’s research enterprise, Sarawak’s healthcare challenges remain formidable.
The state’s 270 clinics serve a population scattered across terrain where road connectivity remains incomplete, and many facilities date from the 1960s and 1970s and require replacement or major upgrading.
The Debak Maternal and Child Health Clinic exemplifies both challenge and response, constructed in 1973 in a building that is almost entirely timber, about 99 per cent, and in dilapidated condition.
In July 2025, the Sarawak government announced RM11 million for complete reconstruction, ensuring safer, modern facilities for rural communities.
Perhaps the starkest contrast between Sarawak’s research excellence and clinical reality appears at Sarawak General Hospital’s cancer centre, where Deputy Premier Dr Sim, while celebrating research achievements, has been blunt about clinical facilities, stating that in Sarawak you go to the cancer department not sick but become sick because the facilities are not ideal and not up to standard.
This assessment is corroborated by peer-reviewed research published in PLOS ONE in 2024, which conducted a comprehensive survey of 443 cancer patients at the central referral centre and identified significant gaps in cancer care delivery.
The study found that while patients were more satisfied with information related to cancer diagnosis, treatment and surgery, they were less satisfied with information pertaining to sexual aspects of care and family planning, psycho-social support and financial support.
The research highlighted those sexual aspects of care and family planning, psychosocial support and treatment monitoring post-discharge were perceived as important but seldom addressed by health care professionals due to lack of professional counsellors, social workers and clinical nurse specialists.
The study also documented that many patients face financial toxicity following a cancer diagnosis, particularly when diagnosed with advanced cancer requiring complex multi-modality treatment, and recommended that written information and educational videos in local indigenous languages may be more suitable for Sarawak’s multi-ethnic population, especially given the high prevalence of breast and cervical cancer amongst young women of reproductive age in Sarawak.
These findings underscore that research excellence in drug development must be matched by attention to supportive care and patient-centred services.
Federal financial constraints have delayed upgrades, and Sarawak’s response of offering RM1 billion in state funding through a partnership model illustrates the state’s evolving approach to healthcare financing.
Under this arrangement, Sarawak would fund construction while the federal Ministry of Health manages operations, similar to the Samarahan Heart Centre model where the state pays RM1 annual rent.
Sarawak’s long-term infrastructure vision encompasses comprehensive trauma centres in each major region, with Deputy Premier Dr Sim arguing that Sarawak needs trauma centres in every major zone because eight hundred kilometres is too far to send patients to a single treatment centre.
Each centre would require CT scanning, neurosurgery, orthopaedics, intensive care, and full support teams, capabilities currently concentrated in Kuching, and the vision reflects Sarawak’s conviction that healthcare planning must respond to geographical reality rather than population distribution alone.
Health Autonomy Under MA63
Sarawak’s pursuit of health autonomy under MA63 gained unprecedented momentum in 2024 when the first technical meeting on health autonomy convened at Wisma Bapa Malaysia, bringing together federal and state leadership including Health Minister Datuk Seri Dzulkefly Ahmad and Deputy Premier Dr Sim Kui Hian. Dr Sim described the meeting as historical and evidence of the highest level of commitment to the Malaysia Agreement 1963, and the meeting established small working committees to examine Sarawak’s comprehensive proposal covering infrastructure, governance, human resources, and legislative matters.
A key autonomy milestone involves establishing a Sarawak Medical Council separate from the Malaysian Medical Council, and Deputy Premier Dr Sim announced in December 2024 that Sarawak would form its own council, working collaboratively with the national body.
This development, described as a major step in achieving health autonomy under MA63, would give Sarawak regulatory authority over medical practitioners in the state while maintaining registration standards and enabling Sarawak-specific workforce policies responsive to local needs. Sarawak’s capacity to fund its health ambitions strengthens its autonomy case, as petroleum sales tax revenue exceeding RM10 billion annually provides fiscal space unavailable to other Malaysian states.
The RM1 billion cancer centre commitment demonstrates willingness to deploy these resources for health.
However, autonomy negotiations involve complex constitutional and administrative questions, with Deputy Premier Dr Sim acknowledging that full implementation will take time and that health autonomy represents a roadmap, not something achievable overnight.
Comparisons with other health systems reveal both progress and distance travelled.
Within Malaysia, Sarawak’s digital health achievement of 73 per cent clinic digitalisation positions it ahead of all other Malaysian states, as no other state has announced a 2026 target for complete clinic digitalisation or allocated equivalent state funding to health information technology.
In clinical research, Sarawak’s concentration of first-in-human trials is unmatched nationally, and while University Malaya Medical Centre and other institutions conduct clinical trials, Sarawak’s penetration of global oncology drug development, with eight of 25 new drugs, places it in a distinct category.
However, in basic health infrastructure indicators, Sarawak faces challenges more similar to Sabah than to Peninsular states, as rural clinic conditions, specialist distribution, and geographical access barriers more closely resemble East Malaysian realities than the denser networks of the west coast.
When compared to Singapore, which represents the region’s gold standard for medical research and healthcare delivery with its biomedical sciences sector contributing approximately S$12 billion annually to manufacturing output and its clinical research infrastructure attracting substantial pharmaceutical investment, Sarawak’s achievement in being selected ahead of Singapore General Hospital for Roche’s solid tumour trial suggests that research excellence can emerge outside established centres.
However, Singapore’s healthcare system spends S$11 billion annually, approximately RM35 billion, which is more than 30 times Sarawak’s health allocation, and supports specialist training across all disciplines.
Sarawak’s niche strategy, focusing on oncology research where individual investigators have built international reputations, offers a pathway to recognition without requiring Singapore-scale investment.
Comparisons with Indonesian Kalimantan, Sarawak’s Bornean context, reveal that while precise healthcare statistics for Kalimantan’s five provinces are difficult to obtain, Indonesia’s national indicators suggest significantly lower healthcare density with Indonesia averaging 0.5 physicians per 1,000 population nationally, and Kalimantan provinces likely below this average due to similar geographical challenges.
Cross-border healthcare flows reflect these disparities, as Indonesian patients from West Kalimantan regularly seek care in Kuching, particularly for tertiary services unavailable in Pontianak, and Sarawak’s private hospitals serve this market, creating economic linkages alongside healthcare provision.
Comparisons with Organisation for Economic Co-operation and Development (OECD) countries reveal both progress and distance travelled, as Malaysia’s national indicators of 2.0 physicians per 1,000 population and 1.9 hospital beds per 1,000 trail OECD averages of 3.6 physicians and 4.4 beds.
Sarawak’s indicators likely approximate national averages for most metrics with some variations, as specialist density outside Kuching falls below national averages while research output exceeds national expectations, and the digitalisation achievement of 73 per cent of clinics compares favourably with OECD primary care digitalisation rates which typically range from 60 to 80 per cent in countries with mature health information systems.
Research Output
The statistical evidence of Sarawak’s transformation is compelling.
In workforce terms, neurosurgery specialists have grown from one in 1998 to 19 today with 15 remaining in public service, while oncology research assistants’ number 40, all funded through research grants rather than government allocation.
In research output, Sarawak has conducted over 255 clinical trials across all phases, with the oncology department alone completing 72 studies, including eight first-in-human trials, and eight of 25 new global oncology drugs have a Sarawak footprint.
Research income exceeds RM50 million annually.
In digital health, 175 of 270 clinics representing 73 per cent have been digitalised, covering approximately 73 per cent of clinic attendees, with Phase 1 state investment of RM10 million and target completion by 2026 for all 271 clinics.
Infrastructure investment includes RM11 million for Debak Clinic reconstruction and a proposed RM1 billion state funding commitment for the cancer centre.
The peer-reviewed literature adds important dimensions to these statistics.
The 2024 PLOS ONE study of 443 cancer patients documented that while treatment-related information satisfaction was adequate, significant gaps existed in psychosocial support, financial counselling, and culturally appropriate communication, with recommendations for educational materials in local indigenous languages.
The 20-year cancer epidemiology studies provide essential population-level data for service planning, documenting incidence trends that reflect Sarawak’s demographic and health transition.
The One Health research collaborations demonstrate Sarawak’s integration into international infectious disease research networks, with studies on vaccine effectiveness contributing to global evidence.
The historical waterborne disease research quantifies the remarkable public health gains since 1963, with dysentery declining more than 200-fold following water supply interventions.
The immediate priority is completing clinic digitalisation by 2026, which requires addressing internet connectivity for 94 remaining clinics, many in areas with limited telecommunications infrastructure. Success would position Sarawak as Malaysia’s first fully digitalised state health system, a foundational achievement for subsequent AI and telemedicine applications.
The proposed RM1 billion cancer centre represents Sarawak’s largest-ever health infrastructure investment, and if realised through the partnership model, it would transform oncology services while demonstrating the viability of state-federal cooperation, though construction timelines, clinical staffing, and service scope remain under negotiation.
Health autonomy negotiations will progress through MA63 committees with technical working groups examining specific proposals, and the establishment of a Sarawak Medical Council, assuming final approval, would give the state regulatory authority matching its growing service capacity.
Sarawak’s research momentum appears sustainable, as the oncology department’s reputation attracts international partnerships and the 40-strong research team provides capacity for continued trial participation, with expansion into other specialties and translation of research findings into clinical practice representing logical next steps.
Determines To Shape Its Own Future
Sarawak’s healthcare journey since 1963 traces an arc from post-colonial scarcity to international recognition.
The state that began Malaysian nationhood with wooden rural clinics and travelling dispensaries now conducts clinical trials that shape global oncology practice.
The neurosurgery department established in 1998 with a single surgeon now fields 19 specialists and advocates for regional trauma centres serving all Sarawakians.
Yet achievement exists alongside persistent challenge. The cancer centre where global research unfolds occupies facilities that Deputy Premier Dr Sim describes as making patients become sick, a characterisation supported by peer-reviewed research documenting gaps in psychosocial support, financial counselling, and culturally appropriate communication.
Rural communities continue travelling hundreds of kilometres for specialist care.
Digitalisation reaches 73 per cent of clinics but cannot substitute for physical infrastructure and clinical workforce.
Health autonomy under MA63 offers Sarawak the opportunity to address these contradictions directly, to plan according to its geography, invest according to its priorities, and regulate according to its needs.
The RM1 billion cancer centre proposal, the RM10 million digitalisation allocation, and the RM11 million Debak Clinic reconstruction demonstrate willingness to fund solutions when federal resources prove insufficient.
Comparative context reveals Sarawak’s distinctive position, neither fully developed by OECD standards yet achieving specific outcomes that exceed many wealthier systems.
The eight new cancer drugs tested in Kuching, the digitalisation rate surpassing most Malaysian states, the research income funding 40 local scientists, the peer-reviewed publications documenting both achievements and remaining gaps, these elements together suggest a system capable of managing its own affairs while acknowledging the work still required.
The MA63 vision of a Malaysian federation where component states retain meaningful autonomy finds expression in Sarawak’s health journey.
From 1963 to 2026, from timber clinics to digital records, from dependency to clinical trials, from the 200-fold reduction in dysentery to the first-in-human oncology trials, Sarawak’s medical story illustrates what becomes possible when a state determines to shape its own future while building the evidence base to guide its way.
References
Ahmad, K., Anchah, L., Ting, C. Y., & Lim, S. E. (2024). Effectiveness of a pharmacist-led, community group-based education programme in enhancing diabetes management: A multicentre randomised control trial. Contemporary Clinical Trials Communications, 38, 101280. https://doi.org/10.1016/j.conctc.2024.101280
Free Malaysia Today. (2025). Sarawak emerges as leading state for first-in-human cancer drug trials.
Jawa, D., Ahmad, S. R., Ooi, C. H., Wahab, M., Bujang, M. A., & Bong, J. J. (2024). Epidemiology of uterine cancer in Sarawak, Borneo, a 20-year review. Asian Pacific Journal of Cancer Prevention, 25(4), 1143–1153. https://doi.org/10.31557/APJCP.2024.25.4.1143
Liew, K. B., & Lepesteur, M. (2006). Performance of the rural health improvement scheme in reducing the incidence of waterborne diseases in rural Sarawak, Malaysia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 100(10), 949–955. https://doi.org/10.1016/j.trstmh.2005.11.018
Lim, M. S. H., Ling, K. W., Lim, C. M., Ooi, C. H., Wahab, M., Bong, J. J., & Bujang, M. A. (2024). Gaps in cancer care in a multi-ethnic population in Sarawak, Borneo: A central referral centre study. PLOS ONE, 19(7), e0296954. https://doi.org/10.1371/journal.pone.0296954
Malay Mail. (2024). Deputy premier: First technical meeting on Sarawak’s health autonomy ‘historical’, shows commitment to MA63.
Ministry of Public Health, Housing and Local Government Sarawak. (2024). Dr Sim: First technical meeting on S’wak health autonomy ‘historical’, shows commitment to MA63.
Premier Department of Sarawak. (2025a). RM11 Million Allocated To Rebuild Maternal & Child Health Clinic In Debak.
Premier Department of Sarawak. (2025b). Sarawak Perlu Autonomi Kesihatan, Wujudkan Pusat Trauma Menyeluruh.
Sin Chew Daily/Medic. (2023). 与中央政府合作 砂出资建医院 捍卫生自主权.
Sin Chew Daily Sarawak. (2024). 实现卫生自主重大进展. 沈桂贤：砂欲设砂医药理事会.
Sin Chew Daily Sarawak. (2025). 沈桂贤：央院临床试8治癌新药 砂跻身国际医研前列.
Suara Sarawak. (2025). Sarawak Sasar Semua Klinik Kesihatan Jalani Transformasi Digital Menjelang 2026.
Thayaparan, S., Robertson, I. D., Amaran, F., Lela, S., Gunasekera, U. C., & Abdullah, M. T. (2015). Seroepidemiological study of leptospirosis among the communities living in periurban areas of Sarawak, Malaysia. The Medical Journal of Malaysia, 70(5), 288–294.
Toh, T.-H., Liaw, C. T., Goh, P. P., & Ooi, C. H. (2023). Effectiveness of vero cell inactivated vaccine against severe acute respiratory infections (SARI) in Sibu, Malaysia: A retrospective test-negative design. Human Vaccines & Immunotherapeutics, 19(1), 2167438. https://doi.org/10.1080/21645515.2023.2167438
TVS. (2025). 73 pct of Sarawak health clinics fully digitalised.
Universiti Malaysia Sarawak, Duke University, & SEGi University. (2025). Integrating One Health research in Sarawak, Malaysia: Addressing emerging and re-emerging infectious disease through international collaboration. One Health, 20, 101027. https://doi.org/10.1016/j.onehlt.2025.101027
Yap, C. H., Ooi, C. H., Wahab, M., Bujang, M. A., & Bong, J. J. (2025). Incidence trends of prostate cancer in Sarawak, Malaysia: A 20-year population-based analysis. Journal of Cancer Research and Clinical Oncology, 151(3), 82. https://doi.org/10.1007/s00432-025-06042-6
